Halozyme Therapeutics announced the company has entered into a global collaboration and exclusive license agreement with Takeda. The agreement provides Takeda with access to Halozyme's ENHANZE® drug delivery technology, the leading proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20), for use with vedolizumab. Vedolizumab is marketed globally as ENTYVIO.
"Our collaboration with Takeda reflects our ongoing commitment to delivering innovative solutions that enhance the patient experience, with the goal of helping patients spend less time managing their therapy and more time living their lives," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "Our new collaboration reinforces the broad applicability and value of the ENHANZE technology across multiple therapeutic areas."
"People living with ulcerative colitis and Crohn's disease, as well as their health care providers, need flexible treatment options that match evolving needs and priorities in disease management," said Robert Hollowell, M.D., Head of Global Product and Launch Strategy, GI and Inflammation at Takeda. "Our collaboration is another example of our commitment to the IBD community and leadership in this therapeutic area. It is an exciting opportunity to potentially enable vedolizumab to benefit even more patients around the world, and integrate even more seamlessly into patients' lives."
Under the terms of the agreement, Takeda will make an upfront payment to Halozyme, and potential future development and commercial milestone payments. Halozyme will also be entitled to up to low-mid single digit royalties on sales of products containing vedolizumab in combination with ENHANZE®.
Crohn's disease and ulcerative colitis are the two main forms of inflammatory bowel disease (IBD), characterized by chronic inflammation of the gastrointestinal tract. Both conditions can result in serious complications. It is estimated that more than 10 million people across the globe will be living with IBD within the next decade, reflecting a growing burden of IBD.
Vedolizumab is a biologic therapy approved (under the trade name ENTYVIO) for intravenous (IV) and subcutaneous (SC) administration (approvals vary by market). ENTYVIO is approved for use in adults with moderately to severely active Crohn's disease or ulcerative colitis.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!